FDA declines to approve Y-mAbs's pediatric cancer drug

 The U.S. Food and Drug Administration on Thursday declined to approve a treatment from Y-mAbs Therapeutics for a rare form of nerve cancer in pediatric patients, dragging its shares 15% lower in extended trade. 

https://www.marketscreener.com/quote/stock/Y-MABS-THERAPEUTICS-INC-46288936/news/U-S-FDA-declines-to-approve-Y-mAbs-s-pediatric-cancer-drug-42457464/